Statins in homozygous familial hypercholesterolemia
| Autor: | Dirk J. Blom, Firth Jc, Adrian David Marais |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Pediatrics
medicine.medical_specialty medicine.medical_treatment Atorvastatin Familial hypercholesterolemia Liver transplantation Pharmacology Hyperlipoproteinemia Type II Pharmacotherapy Medicine Humans Angiology Clinical Trials as Topic business.industry Homozygote nutritional and metabolic diseases medicine.disease Premature atherosclerosis Treatment Outcome lipids (amino acids peptides and proteins) Plasmapheresis Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business Dyslipidemia medicine.drug |
| Zdroj: | Current atherosclerosis reports. 4(1) |
| ISSN: | 1523-3804 |
| Popis: | Homozygous familial hypercholesterolemia is a rare disorder resulting in severe premature atherosclerosis. Drug therapy was previously viewed as inadequate for control of the dyslipidemia, so portacaval shunting, plasmapheresis, and liver transplantation were undertaken to treat this condition. Despite these drastic measures, additional cholesterol-lowering treatment may still be required. Furthermore, there is a need for pharmacologic control until additional measures can be undertaken. The statins, an evolving class of cholesterol-modifying drugs, represent a significant development in the treatment of homozygous familial hypercholesterolemia. The experience with statins in this condition is limited, but some insight into their utility has been gained from studies reviewed in this article. It is recommended that high doses of statins be used in combination with other lipid-modifying strategies for the best control of the dyslipidemia of homozygous familial hypercholesterolemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink